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En muchas disciplinas médicas existen diferencias significativas entre 
las muestras procedentes de estudios experimentales y las muestras 
procedentes de ámbitos clínicos, como es por ejemplo el caso de 
la hipertensión. El objetivo del presente estudio fue comparar las 
muestras procedentes de los ensayos pivotales de fase 3 de nalmefeno 
con la muestra de un estudio de fase 4 realizado recientemente. 
Las características basales de las muestras se compararon mediante 
técnicas univariantes. Se encontraron diferencias significativas entre el 
porcentaje de los participantes consumidores de alcohol de bajo riesgo. 
También se encontraron diferencias en los patrones de prescripción y 
en la toma de nalmefeno, así como en el porcentaje de comorbilidades 
psiquiátricas y adictivas, que fueron muy superiores en el estudio de fase 
4. En su conjunto, estos datos sugieren que en el campo del trastorno 
por uso de alcohol (TUA) existen también diferencias relevantes 
entre muestras procedentes de estudios experimentales y muestras 
procedentes de estudios clínico-observacionales. Este hecho refuerza 
la necesidad de que los estudios de fase 3 sean complementados con 
estudios observacionales de fase 4. 
Palabras clave: Fase 3; Fase 4; Validez externa; Nalmefeno; Trastorno 
por uso de alcohol.
Concerns regarding the external validity of phase-III trials are 
common to many medical disciplines, with relevant discrepancies 
found between experimental and clinical samples in some diseases 
such as hypertension. The aim of this study was to compare the samples 
included in the pivotal, phase-III clinical trials of nalmefene with that 
of a recently conducted phase-IV trial. Baseline characteristics of 
the studies were compared through univariate analysis. Significant 
differences were found in the percentage of low-risk drinkers 
included. Differences were also found in the prescription and intake 
pattern of nalmefene, as well as in the rate of psychiatric and addictive 
comorbidities, which were much higher in the phase-IV study. These 
data suggest that in the field of alcohol use disorders there are also 
relevant differences between experimental and clinical samples, a 
fact that reinforces the need for phase-III trials to be balanced with 
observational, phase-IV trials.
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Alcohol imposes a heavy burden on societies around the world, most of which is inflicted by those who drink heavily, that is, those affected by an alcohol use disorder (Whiteford et al., 
2013). The treatment of AUDs is therefore of high impor-
tance. A combination of psychosocial and pharmacological 
strategies is usually recommended. Regarding pharmaco-
logical treatment, last decades have witnessed the appear-
ance of different compounds with proven efficacy on sev-
eral outcomes. Such is the case of nalmefene, an opiod 
antagonist recently approved for the treatment of alcohol 
patients who aim for a reduction objective. The approval 
was based on three pivotal phase-III trials (Gual et al., 2013; 
Mann, Bladström, Torup, Gual & van den Brink, 2013; van 
den Brink et al., 2013). 
Phae-III trials are a basic and very important step in the 
process leading to drug approval by regulatory agencies. 
They are usually largely sized, randomized trials with a ho-
mogenous study sample. All these characteristics lead to 
high statistical power and high internal validity. 
While experimental designs such as those of phase-III 
studies are essential for internal validity assessment and 
are the cornerstone of drug efficacy assessment, it has 
been extensively noted in many areas that, usually, exter-
nal validity remains disproportionally neglected (Dekkers, 
von Elm, Algra, Romijn & Vandenbroucke, 2010; Pearson 
& Coomber, 2010; Rothwell, 2005). This fact might yield 
relevant consequences, such as the fact that patients from 
experimental settings might differ significantly from pa-
tients in real world settings (Hoertel et al., 2014; Uijen, 
Bakx, Mokkink & van Weel, 2007), ultimately jeopardiz-
ing the feasibility, applicability and even the relevance of 
experimental findings(Persaud & Mamdani, 2006).
In this context, previous studies in several diseases such 
as hypertension, social anxiety rheumatoid arthritis and 
others(Farahani, Levine, Gaebel & Thabane, 2005), have 
found that phase-III and phase-IV patients are not always 
similar, a fact that could have relevant implications. There-
fore, we believe it is also necessary to evaluate, in the field 
of alcohol use disorders, whether patients in “real-life” are 
comparable to patients of previous experimental studies, 
and what differences might exist. This is in fact, one of the 
reasons leading to the need of phase-IV studies (Linden, 
1984).
In the present paper we aim at comparing the baseline 
characteristics of patients recently enrolled in a phase-IV 
trial of nalmefene with those of patients who participated 
in the phase-III trials. 
Method
The present study compared patients from two differ-
ent types of studies. The first group of patients belongs 
to an observational, multisite, single arm, phase 4 study 
conducted among alcohol dependent outpatients taking 
nalmefene for the first time as a treatment for alcohol use 
disorder. To be enrolled in this phase-IV trial, patients had 
to be adults (≥18 years) diagnosed with alcohol depen-
dence according to the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-IV TR) or the International 
Classification of Diseases (ICD-10) criteria who according 
to routine clinical criteria, had been started on nalmefene 
for the first time. The study consisted of 4 visits: baseline, 
1 month, 6 months and 12 months. Patients continued to 
receive their usual treatment independent of study visits 
and procedures. 
The second group consisted of patients who participat-
ed in the three phase-III trials of nalmefene. Data from 
these patients was gathered from existing publications in 
the literature. Phase-III trials were kept independent of 
each other for study comparisons. Therefore, a total of 4 
groups were formed. Each phase-III trial was compared to 
the phase-IV study. All available variables for the 4 stud-
ies at baseline were included. Statistical comparisons were 
conducted with univariate tests (T-test or chi-square de-
pending on variable type). 
Results
A total of 110 patients were included from 4 sites in 
the Spanish region of Catalonia, between 2015 and 2016. 
A full description of the phase-IV study results is available 
elsewhere (Barrio, Ortega, Guardia, Roncero, Yuguero & 
Gual, 2018) . Table 1 illustrates the differences between 
this study and the phase III trials of nalmefene regarding 
the main study variables at baseline. 
Important differences were found regarding the per-
centage of low drinking risk level, with the present study 
showing a much higher rate (45%) as compared to the ES-
ENSE trials (1-5%). Consequently, in the high/very high 
categories, numbers were reversed, with 38% of patients in 
this study allocated to this category, as compared to 76-78% 
in the phase III trials. Another illustration of these relevant 
differences is the fact that in this study, mean alcohol con-
sumption (60.4 g/day) was significantly lower (85-92 g/day 
in ESENSE trials).
Also relevant, we found a significantly lower prevalence 
of family history of alcohol problems in our sample. Finally, 
when comparing the percentage of days with study medi-
cation intake, a higher proportion in the phase-IV trial was 
observed. Also relevant is the fact that the number of pa-
tients taking nalmefene on a daily basis was higher. Given 
the inclusion criteria of phase-III tirals, addictive comorbid-
ities were only present in the phase-IV study. Similarly, only 
the SENSE trial allowed psychiatric comorbidities among 
patients, which were nonetheless much less frequent than 
in the phase-IV trial. 
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Discussion
This study found significant differences between phase-
IV and phase-III patients taking nalmefene. When com-
pared to phase-III trials, patients in real settings showed 
a higher rate of both addictive and psychiatric comorbid-
ities, a fact that is in sharp contrast with the samples of 
randomized, controlled studies, which are usually more 
restrictive in their inclusion criteria. In fact, the high rate 
of psychiatric comorbidities in alcohol patients is a well 
documented phenomenon (Fein, 2015; Flensborg-Madsen 
et al., 2009). This finding supports the criticisms targeted 
at the external validity of experimental studies (Persaud & 
Mamdani, 2006) and at the same time suggests that, studies 
like the SENSE trial (van den Brink et al., 2014), where pa-
tients with psychiatric comorbidities were included, should 
be the norm rather than the exception. 
It should also be noted that a great number of patients 
in the phase-IV trial were already labeled as low-risk drink-
ers at baseline. In fact, almost half of the patients were 
considered low-risk drinkers at study entry, a fact that at 
first sight could seem contradictory to nalmefene thera-
peutic indications. It should be noted, however, that risk 
assessment for phase-IV study purposes was based on the 
previous 28 days. It is probable that clinicians, when decid-
ing the risk category of patients, take into account a lon-
ger timeframe. Also, similar to what has been observed in 
phase-III trials, it is possible that the mere fact of patients 
deciding to enter into treatment leads to significant reduc-
tions in drinking. Interestingly, the percentage of low risk 
drinkers in the phase-IV trial is very similar to that of phase-
III trials if we add up the baseline low risk drinkers and the 
low risk drinkers prior to nalmefene initiation. 
Age at onset of drinking problems was another variable 
showing clear differences. While real differences could be 
expected between real practice and experimental studies, 
it could also be due to different methods of recollection. 
While a younger age of onset of drinking problems could 
suggest a greater disease severity, baseline alcohol parame-
ters were, conversely, milder in the phase-IV study sample, 
with lesser heavy drinking days and lesser mean alcohol con-
sumption. It also looks like patients in the phase-IV trial had 
a superior rate of medication intake. In fact, results of the 
phase-IV (Barrio et al., 2018) suggest that, despite being la-
beled as an “as-needed” medication, patients and clinicians 
in real world practice will frequently use it on a scheduled, 
daily basis. 
Several limitations apply to this study. The most relevant 
is the different design of phase-IV and phase-III trials, a fact 
Table 1. Main sociodemographic characteristics of included patients and comparison with phase III trials






Age: mean (SD) 44.4 (9.4) 51.0 (10.1)* 45.1 (10.7] 44.3 (11.2]
Sex male (%) 66.4% 66.6% 74.3% 77.2%*
Higher education (%) 27.3% 32.4%
Age at the Onset of Drinking Problems: mean (SD) 23 (12.4) 37.9 (13.1)* 32.6 (10.8)* 33.4 (11.6)*
Drinking Risk Level
Low (%) 45.5% 3%* 1.4%* 15.5%*
Medium (%) 16.4% 22.2% 19.0%  32.8%*
High (%) 21.8% 37.3%* 36.0%* 29.1%
Very High (%) 16.3% 39.9%* 43.6%* 22.4%
g-Glutamyltransferase (IU/L) : mean (SD) 84 (128.2) 51.7 51.8 40.9
Alanine Aminotransferase (IU/L) : mean (SD) 29.2 (15.5) 29.2 28.7 28.5
Previously Treated for Alcohol Dependence (%) 46.4% 29.7%* 39.7% 33.6%*
Previously Treated for Alcohol Withdrawal (%) 30% 19.6%* 15.9%* 26.9%
Personal history of psychiatric problems (%) 36.4% 3.7%*
Family History of Alcohol Problems (%) 48.2% 62.4%* 60.1%* 51.7%
Addictive comorbidities*** (past or present) (%) 65.5%
Percentage of days taking study medication (%) 64% 48%* 57% 48.4%*
Monthly heavy drinking days (baseline) : mean (SD) 13.5 (11) 19.5 (7.3)* 19.7 (7.0)* 14.1 (6.2)
Mean alcohol consumption (grams per day; baseline) : mean (SD) 60.4 (74.6) 84.8 (42.1)* 92.2 (46.9)* 68.6 (40.0)
 
Note. *=significant at p<0.05 when compared to phase IV study values with univariate tests (t-student or chi-square). 
** defined as the presence of diabetes, hypertension, high blood cholesterol or any other significant medical condition.
*** defined as any substance use disorder (except nicotine dependence), past or current, as clinically evaluated in the first visit of the study.
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that implies caution when interpreting the comparisons 
undertaken in this study. Also, it is important to mention 
that the phase-IV trial included patients from 4 different 
sites, all belonging to the same city. In this sense, phase-III 
trials had a much wider representation, with patients from 
different countries being included. 
Conclusion
All in all we believe this study suggests that, as previously 
shown in other diseases, samples from experimental stud-
ies might differ in some aspects from patients in routine 
clinical practice. While efforts targeted at increasing phase-
III trials’ external validity should be encouraged, this study 
also confirms that phase-IV studies are indeed a crucial 
part of the research process.
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